A once-monthly GLP-1 receptor agonist for treatment of diabetic cats

There is growing evidence that peptidic glucagon-like peptide-1 receptor agonists (GLP-1RA), such as exenatide, may provide useful therapeutic options for treatment of feline diabetes. However, because such drugs are administered subcutaneously, it is desirable that they be long-acting and not require frequent injections. We have developed a chemically controlled delivery system to support half-life extension of peptidic therapeutics. Here, the peptide is covalently attached to hydrogel microspheres by a self-cleaving beta-eliminative linker; after subcutaneous injection of the microspheres, the peptide is slowly released from the depot to the systemic circulation. Using this technology, we developed a delivery system that supports once-monthly administration of a stable exenatide analog, [Gln(28)]exenatide, in rodents (Schneider, et al, ACS Chem Biol 12, 2107 to 2116, 2017). The purposes of the present study were a) to demonstrate pharmacokinetic and pharmacodynamic similarities of the deamidation-sensitive GLP-1RA exenatide and the closely related, more stable [Gln(28)]exenatide and b) to develop a long-acting GLP-1RA in cats. The results show that exenatide and [Gln(28)]exenatide injected intravenously or subcutaneously at 10 mu g/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of similar to 40 min-but subcutaneously administered [Gln(28)]exenatide has superior bioavailability-93% for [Gln(28)]exenatide vs 52% for exenatide. The results also show that exenatide and [Gln(28)]exenatide have similar insulinotropic activities in the cat during a high-dose intravenous glucose tolerance test; they increased the area under the curve (AUC) for insulin to a similar extent but had no effect on glucose AUC. Finally, subcutaneous injection of a microsphere-[Gln(28)]exenatide conjugate containing an appropriate self-cleaving linker in the cat provides plasma [Gln(28)] exenatide with a half-life of about 40 d vs 40 min with the injected free peptide. Hence, the large body of information available for exenatide can be used to facilitate clinical development of [Gln 28 ]exenatide as a treatment for feline diabetes, and the microsphere-[Gln(28)] exenatide conjugate is quite suitable for once-monthly subcutaneous administration of the peptide in the cat. (C) 2019 Elsevier Inc. All rights reserved.